PBGRX Performance — Polen Global SMID Company Growth Fund, Investor Class

Data updated: 2024-07-15

In the 12 months to Apr 2024 the fund took in a net $11.6M, and assets reached $10.47M.

PBGRX Growth of $100

What $100 invested in Polen Global SMID Company Growth Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Global Mid-Cap Growth category average over the same months.

PeriodPBGRXCategory average
Since data start (Aug 2023 – Apr 2024)$96$101

PBGRX Annual Returns

Calendar-year total returns of Polen Global SMID Company Growth Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.

YearTotal return
2024 (Jan–Apr)−6.52%
2023 (Aug–Dec)+3.05%

PBGRX Monthly Returns

Monthly total returns as reported on SEC Form N-PORT.

YearJanFebMarAprMayJunJulAugSepOctNovDec
2024−5.1%+4.9%+0.6%−6.7%————————
2023———————−0.5%−5.5%−8.2%+10.2%+8.2%

PBGRX Risk

Risk measures from monthly returns over Aug 2023 – Apr 2024.

  • Best month: +10.19% (Nov 2023)
  • Worst month: −8.16% (Oct 2023)

PBGRX Fund Flows

Monthly money in and out of Polen Global SMID Company Growth Fund, from SEC Form N-PORT.

  • 12-month net flow: $11.6M
  • 12-month gross sales (incl. reinvestments): $7.2M
  • Sales ÷ redemptions: -1.68×
MonthSalesRedemptionsNet flow
Apr 2024$49K$98K−$49K
Mar 2024$21K$282K−$261K
Feb 2024$259K$200K$60K
Jan 2024$56K−$314K$370K
Dec 2023$511K−$1.8M$2.3M
Nov 2023$15K−$436K$451K
Oct 2023$67K−$219K$286K
Sep 2023$70K−$2.0M$2.1M
Aug 2023$6.2M−$23K$6.2M
Jul 2023$37K$0$37K
Jun 2023$250−$62K$63K
May 2023$250$0$250

PBGRX Assets Under Management

Net assets of Polen Global SMID Company Growth Fund by report date, from SEC N-PORT filings.

Report dateNet assets
2024-04-30$10.47M
2024-01-31$10.87M
2023-10-31$11.40M
2023-07-31$9.74M
2023-04-28$9.41M
2023-01-31$9.35M
2022-10-31$7.45M
2022-07-29$8.49M
2022-04-29$7.87M
2022-01-31$3.99M

For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.